Are mesenchymal stem cells still effective in acute GvHD management?

Basit Öğe Kaydı
dc.contributor.authorUlu, Bahar Uncu
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorTiryaki, Tarik Onur
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKorkmaz, Gulten
dc.contributor.authorNamdaroglu, Sinem
dc.date.accessioned2026-04-04T13:34:50Z
dc.date.available2026-04-04T13:34:50Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractObjective: Graft-versus-host disease (GvHD) is a common and serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly impacting transplant efficacy. In the treatment of GvHD, numerous therapeutic approaches have been explored, with mesenchymal stem cells (MSCs) emerging as a prominent immunomodulatory option. We aimed to evaluate efficacy and outcomes of using MSCs for steroid refractory acute GVHD (SR-aGvHD) management. Materials and Methods: We retrospectively analyzed data from 36 patients' who received MSCs for treatment of SR-aGvHD following allo-HSCT between 2018 and 2024 from nine transplantation centers in T & uuml;rkiye. The product consisted of umbilical cord-derived allogeneic MSCs, which were administered intravenously. Results: Our cohort was at the median age of 39 years (range: 19-61 years), with aGvHD diagnosed at a median of two months after allo-HSCT. More than half of the patients (58.3%) classified as high-grade aGvHD according to the Minnesota risk scoring. Cord blood-derived MSCs were administered at a median dose of 3.45 (range: 0.8-5) million MSCs/kg, with a median of 3th (range: 2-5) line treatment. The rate of responses exceeding partial response (PR) was approximately 20% at the first month, increasing to 24% at the second month. The six-month survival rate was 33%, with 46% of mortality attributed to sepsis and 12.5% related to GvHD. Multivariate analysis indicated that increasing age (>= 35 years) and lower platelet counts (<= 75 x10(9)/L) were associated with higher mortality (p<0.05). Conclusion: MSC therapy has shown promising potential in improving response rates in aGvHD treatment, with efficacy enhanced by younger age and higher platelet counts.
dc.identifier.doi10.1016/j.transci.2024.104051
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1
dc.identifier.orcid0000-0001-6872-3780
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.orcid0000-0002-6230-9519
dc.identifier.orcid0000-0001-5083-6306
dc.identifier.orcid0000-0002-7222-499X
dc.identifier.pmid39721135
dc.identifier.scopus2-s2.0-85212835484
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2024.104051
dc.identifier.urihttps://hdl.handle.net/11616/109412
dc.identifier.volume64
dc.identifier.wosWOS:001396667900001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectMesenchymal stem cells
dc.subjectHematopoietic stem cell transplantation
dc.subjectGraft vs host disease
dc.titleAre mesenchymal stem cells still effective in acute GvHD management?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu